GLP-1 Receptor Agonist Market (2025 - 2030)

GLP-1 Receptor Agonist Market Summary

The global GLP-1 receptor agonist market size was estimated at USD 53.46 billion in 2024 and is projected to reach USD 156.71 billion by 2030, growing at a CAGR of 17.46% from 2025 to 2030. The launch of new glucagon-like peptide 1 (GLP-1) receptor agonist products, a strong product pipeline for both diabetes & obesity applications, and the high efficacy of these drugs are anticipated to propel the market.

In May 2024, Innovent Biologics announced that its type 2 diabetes candidate, mazdutide, outperformed Eli Lilly’s Trulicity (dulaglutide) in a Phase III trial. The study established that mazdutide was superior in glycemic control and provided numerous cardiometabolic benefits, comprising weight loss & improvements in blood lipid levels, liver enzymes, serum uric acid, & blood pressure.

Furthermore, other companies like Boehringer Ingelheim International GmbH, Carmot Therapeutics, Inc., D&D Pharmatech, Lilly (Eli Lilly and Company), and Hanmi Pharm. Co., Ltd, is also involved in developing new glucagon-like peptide 1 drugs. For instance, in October 2023, Carmot Therapeutics, Inc. published preliminary results from the single ascending dose (SAD) phase of the ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) that is presently being assessed in a first-in-human clinical trial in individuals who are overweight or obese. Thus, increasing research in the field of GLP-1 receptor agonists is expected to drive market growth.

Moreover, the rising prevalence of obesity and diabetes is expected to drive the market’s growth. The overweight and obese population is at a high risk of developing diabetes and cardiovascular illness. Worldwide obesity rates are rising, and it is widely acknowledged that this is one of the major public health issues of the present day. According to the World Heart Federation's global estimate, almost 2.3 billion children and adults worldwide suffer from obesity and overweight. In addition, according to the Obesity Action Coalition (OAC), over 90% of individuals diagnosed with type 2 diabetes are either overweight or have some degree of obesity. Therefore, the rising obese population and diabetes population are driving the demand for GLP-1 receptor agonist drugs for treatment worldwide.

The high advantages associated with the use of GLP-1 drugs over other medicines and increasing investment in R&D of new GLP-1 drugs drive market growth. Several GLP agonists have been linked to weight loss or weight neutrality, which is advantageous for diabetics since obesity frequently makes the disease worse. The lowering of appetite and the delayed stomach emptying contribute to the weight loss effect. Moreover, in November 2023, Novo Nordisk revealed its intentions to invest roughly 16 billion Danish kroner in developing GLP-1 drugs. This is roughly equivalent to USD 2.32 billion (€2.14 billion). These initiatives are anticipated to drive the market's growth.

Market Concentration & Characteristics

The degree of innovation in the market includes technological advancement in the field of medical research and development. For example, GLP-1 receptor agonists have recently been combined with other unique bioactive peptides. For instance, the sequences of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) are combined in tirzepatide, a single molecule, to form a so-called co-agonist that is effective in treating a patient with diabetes.

To improve their position in the market, several firms participate in mergers and acquisitions. By using this tactic, businesses can enhance proficiency, diversify their offerings, and boost capacities. For instance, in December 2023, Roche acquired Carmot Therapeutics (CRMO.O) for USD 2.7 billion in upfront payments, adding the company to the roster of competitors vying to take on Novo Nordisk and Eli Lilly and Company, the industry leaders in weight-loss medication manufacturing.

Regulatory bodies are becoming more aware of the importance of real-world evidence (RWE) in completing the picture of clinical trial data to support post-marketing surveillance and regulatory decisions. Information about the long-term efficacy, safety, and usage patterns of GLP-1 receptor agonists in actual clinical practice can be gained via observational studies, electronic health records, and patient registries.

There are currently seven GLP-1 receptor agonists on the market: semaglutide, liraglutide, exenatide, lixisenatide, dulaglutide, and oral semaglutide. Healthcare practitioners also recommend alternative antidiabetic drugs such as metformin, DPP-4 inhibitors, sulfonylureas, SGLT-2 inhibitors, or insulin to patients where GLP-1 receptor agonists are deemed unsuitable or poorly tolerated.

Expanding regional markets makes it easier for developed and developing nations to obtain effective medications. These strategies include collaborating with local healthcare providers, promoting early diagnosis and treatment of diabetes, and offering reimbursement options tailored to the needs of different healthcare systems.

Product Insights

The Ozempic segment dominated the market and accounted for a share of 34.17% in 2024. Ozempic is a brand-name U.S. FDA-approved prescription drug used to treat adults with type 2 diabetes. The increasing type 2 diabetes population and the high safety and efficacy of the drug over other available GLP-1 receptor agonist drugs impact positively on the adoption of the drug.

In March 2024, Novo Nordisk A/S’s drug Ozempic showed a delay in the development of chronic kidney disease (CKD) and reduced the risk of death and cardiac events by 24% in diabetes patients. This clinical trial result encourages physicians to prescribe Ozempic to children and adolescents with type-2 diabetes as a course of treatment, thereby boosting drug adoption worldwide.

Zepbound is expected to grow at a significant growth rate from 2025 to 2030. This growth can be attributed to its worldwide approval of a drug and high demand due to its high efficacy and tolerability. In August 2024, Eli Lilly and Company achieved a significant supply milestone by launching single-dose vials of Zepbound, one of its widely popular weight-loss medications. These new vials are expected to be priced at least 50% lower than the existing versions of Mounjaro and Zepbound.

Application Insights

The type 2 diabetes mellitus segment dominated the market in 2024 and is expected to grow at a CAGR of 17.06% over the forecast period. This can be attributed to the increased prevalence of type-2 diabetes mellitus and the wide availability of GLP-1 receptor agonists for its treatment. According to the World Health Organization (WHO), more than 95% of people across the globe suffer from diabetes disease. Type 2 diabetes is referred to as adult-onset or non-insulin-dependent disease and is exclusively found in adults, but it is now becoming more common in children owing to changed eating habits. Currently, there are several GLP-1 receptor agonist drugs such as Dulaglutide (Trulicity), Exenatide (Byetta), Exenatide extended-release (Bydureon), Liraglutide (Victoza), and others are currently used to treat a patient with type 2 diabetes mellitus. Thus, the rising incidence of type-2 disease is anticipated to boost demand for GLP-1 drugs used for its treatment.

The obesity segment is anticipated to grow significantly during the forecast period. This growth can be attributed to the rising obese population and the approval of a new GLP-1 receptor agonist drug for its treatment worldwide. According to a research study released in 2024 by the NCD Risk Factor Collaboration (NCD-RisC), globally over 880 million adults and 159 million children and adolescents between the ages of 5 and 19 years are affected by obesity. Currently, high-dose liraglutide and semaglutide are given to obese patients as per the U.S. FDA-mentioned dosage form due to the weight-loss effects of these GLP-1 agonists. Thus, approval and launch of new GLP-1 drugs for the treatment of obesity is expected to drive market growth.

Route Of Administration Insights

The parenteral segment held the largest revenue share in 2024 and is expected to grow at a CAGR of 17.42% from 2025 to 2030. This dominance can be attributed to the wide availability of GLP 1 agonists for treating patients with diabetes and its high advantages over other drug administrations, such as high efficacy. Some of the parenteral GLP -1 receptor drugs approved for treatment include Dulaglutide (Trulicity), Exenatide extended release (Bydureon base), Exenatide (Byetta), Semaglutide (Ozempic), Liraglutide (Victoza, Saxenda), Lixisenatide (Adlyxin), and Semaglutide (Rybelsus). The worldwide approval of a new parenteral drug is expected to drive market growth.

The oral route segment is anticipated to grow rapidly from 2025 to 2030. Oral GLP-1 receptor agonist plays a significant role in treating patients with type 2 diabetes disease. Currently, Semaglutide (Rybelsus) is approved by the U.S. FDA to treat patients with diabetes. In May 2023, in the global OASIS initiative, Novo Nordisk released the major findings from OASIS 1, a phase 3a trial. 667 individuals with obesity or overweight participated in the 68-weesk OASIS 1 effectiveness and safety trial, which compared once-daily oral semaglutide 50 mg for weight control versus a placebo. At week sixty-eight, an oral semaglutide 50 mg was shown to provide a statistically significant and superior weight loss when compared to a placebo. The positive results from such studies are anticipated to drive market growth.

Distribution Channel Insights

The hospital pharmacies segment held the largest revenue share of 55.09% in 2024. The growth of hospital pharmacies has facilitated the integration of several healthcare components, increased inpatient visits for diabetes and obesity consultations, and improved customer convenience in acquiring GLP-1 medications. The aging population, rising incidence of diabetes, and availability of skilled staff are some factors driving hospitalization, which significantly affects segment growth. Prescription drugs and related product demand increase in line with hospital admission, which benefits hospital pharmacies' expansion.

The online pharmacies segment is anticipated to grow from 2025 to 2030. The primary driver of the segment is the expansion of internet connectivity. Furthermore, patients seeking a hassle-free way to purchase medications and healthcare items are drawn to online platforms due to their ease of use, accessibility, and increasing digitization, influencing segment growth. Another factor propelling the growth of online pharmacies is the ease of getting prescriptions and over-the-counter treatments from home, with doorstep delivery available. Thus, the growing number of diabetes cases is anticipated to drive market growth during the forecast period.

Regional Insights

North America GLP-1 receptor agonist market accounted for 77.72% of revenue share in 2024. Established brands including liraglutide (Victoza), dulaglutide (Trulicity), exenatide (Byetta/Bydureon), and semaglutide (Ozempic) dominate the GLP-1 receptor agonist market in North America. These drugs have gained a lot of traction among patients and healthcare professionals due to their proven ability to lower cardiovascular risk, improve glycemic management, and encourage weight loss.

U.S. GLP-1 Receptor Agonist Market Trends

The U.S. GLP-1 receptor agonist market is accounted for the largest revenue share in the North American region. Type 2 diabetes accounts for the majority of diabetes cases in the U.S., which has one of the highest prevalence rates of the disease worldwide. It is becoming increasingly severe due to the increased prevalence of obesity and sedentary lifestyles, which is increasing the need for efficient treatments like GLP-1 receptor agonists. Furthermore, the high adoption of the medication is further driving market growth. For instance, according to a poll published by the American Medical Association in 2024, around 16% of U.S. adults, 1 in 8 individuals, have used GLP-1 drugs, with the major drug used being semaglutide marketed as Ozempic or Wegovy.

Europe GLP-1 Receptor Agonist Market Trends

The Europe GLP-1 receptor agonist market was a lucrative region in this industry. The region has a sizable population base, including an elderly population that is particularly vulnerable to diabetes and obesity. Due to this demographic trend, the demand for GLP-1 Receptor Antagonists has surged in Europe.

The UK GLP-1 receptor agonist market is projected to expand in the future. Pharmaceutical companies are always devising innovative ways to formulate GLP-1 receptor agonists to increase patient compliance and convenience. For instance, semaglutide has been developed and commercialized under brand names like Wegovy to treat patients with obesity. This drug approval is expected to drive market growth market growth.

France GLP-1 receptor agonists market is affected by patient preferences and adherence to treatment plans. Patients' decisions and adherence to treatment may be influenced by variables like side effect profiles, frequency of dose, and mode of administration (e.g., injectable vs. oral). Thus, the development and commercialization of a new safe and effective GLP-1 drug is expected to boost market growth.

TheGLP-1 receptor agonists market in Germany is expected to grow over the forecast period due to the large availability of GLP -1 drug for the treatment of diabetes and obesity, The German market offers several GLP-1 receptor agonists, including Ozempic, Victoza, Trulicity, and Byetta/Bydureon. A medication's competitive market share in Germany is influenced by numerous factors, including price, dose frequency, safety profile, and efficacy.

Asia Pacific GLP-1 Receptor Agonist Market Trends

Asia Pacific GLP-1 receptor agonists market is anticipated to witness the fastest growth in the GLP-1 receptor agonist market. The region's growing healthcare sector, sizable target population, and high unmet clinical needs are some factors projected to provide significant growth potential. For instance, key companies like Novartis AG and Eli Lilly and Company operating in the region continuously focus on developing innovative GLP-1 Receptor Agonist solutions for the treatment of diabetes and obesity.

TheGLP-1 receptor agonists market in China is anticipated to rise dramatically due to factors including the country's growing urbanization, changing lifestyles, rising type 2 diabetes prevalence, and the expansion of its healthcare system. Furthermore, key players operating in the market constantly focus on developing novel therapeutics. For instance, in April 2024, Aurisco Pharmaceutical launched a state-of-the-art peptide manufacturing facility in Yangzhou, China, which was set to commence operations in mid-2024.

JapanGLP-1 receptor agonist market is expected to grow over the forecast period. Japan's rising aging population and changing lifestyle driving the prevalence of type 2 diabetes and fueling demand for GLP-1 receptor agonist drugs in the country.

Latin America GLP-1 Receptor Agonist Market Trends

The GLP-1 receptor agonist market in Latin America is expected to grow rapidly. The region has a rapidly growing population and increasing urbanization rates. Urbanization often leads to lifestyle changes such as dietary habits, tobacco use, and stress, which can contribute to the prevalence of diabetes diseases.

BrazilGLP-1 receptor agonist market is expected to grow over the forecast period due to the growing awareness of the importance of diabetes diagnosis and treatment among the Brazilian population. As a result, individuals are becoming more proactive in seeking preventive care and treatment for diabetes diseases, driving the demand for GLP-1 Receptor Agonists in the country.

Middle East & Africa GLP-1 Receptor Agonist Market Trends

The GLP-1 receptor agonist market in the Middle East & Africa is driven by the high prevalence of diseases due to numerous factors such as poor health hygiene practices, growing use of GLP drugs, and inadequate access to diabetic care.

Saudi Arabia GLP-1 receptor agonist market is driven by initiatives undertaken by educational initiatives and public health campaigns to raise awareness of diabetes and obesity among the general population. As a result, the government is focusing on offering safe and low-cost treatment for diabetes and the obese population. This is expected to drive demand for GLP-1 receptor agonists in the country.

Key GLP-1 Receptor Agonist Company Insights

Some leading players operating in the market include AstraZeneca, Sanofi, Novo Nordisk A/S, and Eli Lilly and Company. Key players use existing customer bases in the region to prioritize maintaining high-quality standards and gain high market size access. This strategy is useful for brands that have already built market positions. These players are heavily investing in infrastructure, allowing them to process & analyze a large volume of samples efficiently. Moreover, companies undertake various strategic initiatives with other companies and distributors to strengthen their presence.

Hanmi Pharm. Co., Ltd, Eccogen, and D&D Pharmatech are some emerging players in the market. These companies focus on achieving funding support from government bodies and healthcare organizations aided with novel launches to capitalize on untapped avenues.

Recent Developments

• In August 2024, Eli Lilly and Company announced that Tirzepatide (Zepbound and Mounjaro) reduced the risk of developing type 2 diabetes by 94% in adults with prediabetes and obesity or overweight, according to the SURMOUNT-1 study. The 176-week trial showed an average 22.9% weight loss with the 15 mg dose. In addition, Tirzepatide demonstrated consistent safety and tolerability.

• In July 2024, Amylyx Pharmaceuticals acquired Avexitide, a GLP-1 receptor agonist, from Eiger Biopharmaceuticals, Inc., with FDA breakthrough therapy designation for treating Postbariatric Hypoglycemia (PBH) and congenital hyperinsulinism. Avexitide showed significant efficacy in reducing severe hypoglycemic events in Phase 2 trials and is set to enter Phase 3 trials for PBH in early 2025.

• In February 2024, Eli Lilly and Company anticipated launching Mounjaro, its highly successful diabetic medication and obesity treatment, in India as early as next year if it passes an ongoing regulatory evaluation. This product is expected to impact Indian market growth positively.

• In January 2024, Novo Nordisk A/S announced research alliances with two U.S. biotech firms. As part of its efforts to keep ahead of big pharma in discovering more medicines for cardiometabolic disorders

• In November 2023, Novo Nordisk A/S announced that it planned to introduce its immensely popular anti-obesity medicine, Wegovy, in Japan on February 22, marking its first launch in Asia, even as it struggles to keep up with demand in existing regions.

GLP-1 Receptor Agonist Market